APLS is expanding SYFOVRE's potential with a phase 2 study combining it with siRNA APLS-3007, aiming to enhance efficacy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback